Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HLS Therapeutics Inc. (T:HLS)

Business Focus: Retail - Drugs without Grocery

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for HLS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Feb 27, 2020 15:00 ET
HLS Therapeutics to Host Q4 and Fiscal 2019 Financial Results Conference Call
TORONTO, Feb. 27, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its fourth quarter and fiscal 2019 financial results by press release at 6:30 a.m. Eastern Time on Thursday, March 19, 2020. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrick
Read full article
Jan 28, 2020 05:30 ET
HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)
Vascepa to be available on or about February 18, 2020, supported by a national Cardiovascular salesforce Vascepa becomes the first and only Health Canada-approved medication for reducing cardiovascular risk beyond cholesterol-lowering therapy in the studied high-risk patients approved for treatment Vascepa is supported by data from the REDUCE-IT® trial, an international 8,179 patient outcomes study that showed a 25% placebo-controlled risk reduction in the first occurrence of major adverse cardiovascular events Cardiovascular disease is the number one killer globally1 and HLS is taking steps
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.47
--
--
Price to Sales - TTM
8.72
5.70
3.11
Price to Book - most recent quarter
2.60
1.42
2.07
Price to Cash Flow per share - TTM
19.50
19.50
10.74
Price to Free Cash Flow per share - TTM
17.19
17.19
26.97
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Feb 15, 202028,576-5,571
Jan 31, 202034,147-24,318
Jan 15, 202058,465-68,465
See Short Report

Business Summary

Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers

HLS Therapeutics Inc is a Canada-based company specialized in the pharmaceutical industry. The Company acquires and distributes commercial stage and branded pharmaceutical drugs for the North American markets. The Company focuses mainly on treatment products for the central nervous system and cardiovascular specialties in Canada. Its product pipeline includes clozaril, for the treatment of schizophrenia disorders; absorica, for treatment of skin disease, such as acne; vascepa, for the treatment of hypertriglyceridemia, and trinomial for cardiovascular risk reduction. Apart from its operation in a number of regions in Canada, such as Toronto, Ontario, and Montreal, the Company also operates in the United States.

See business summary

Twitter

Search (past week) for $HLS.CA

  • No tweets found